Identification and regulation of EMT cells by laser stimulation.
Cells undergoing epithelial-to-mesenchymal transition (EMT) exhibit significant plasticity, making them more tumorigenic, invasive, and stem-like.
APA
Zhao X, Zhu G, et al. (2025). Identification and regulation of EMT cells by laser stimulation.. APL bioengineering, 9(2), 026119. https://doi.org/10.1063/5.0268350
MLA
Zhao X, et al.. "Identification and regulation of EMT cells by laser stimulation.." APL bioengineering, vol. 9, no. 2, 2025, pp. 026119.
PMID
40438388
Abstract
Cells undergoing epithelial-to-mesenchymal transition (EMT) exhibit significant plasticity, making them more tumorigenic, invasive, and stem-like. PLCG2 has been identified as being linked to EMT. Specifically, the PLCG2-high subpopulation of tumor cells shows strong correlations with metastasis. However, it remains unclear whether PLCG2 serves as a direct driver of EMT. In this study, we employ an photostimulation method using tightly focused femtosecond-laser scanning to activate intracellular Ca signaling and induce PLCG2 upregulation. By constructing a subcutaneous tumor model with prostate cancer PC3 cells and single-cell RNA sequencing, we identify distinct cell populations, including cancer stem cells, epithelial tumor cells, proliferating cells, and EMT cells. Upon photostimulation, EMT cells are notably expanded among the primary tumor cells, while epithelial tumor cells decrease in number. During the tumor progression, treatment with a specific PLCG2 inhibitor effectively suppresses the growth of the primary tumor but has no significant impact on metastatic cells. These findings offer valuable insights into the role of PLCG2 in regulating EMT and tumor development.
같은 제1저자의 인용 많은 논문 (5)
- Heterogeneous Magnetic Resonance Nanoprobe for Assisting Liver Fibrosis Three-Dimensional Reconstruction and Cascaded Therapy.
- Performance of latest AI models, RAG, and MCP on lung cancer-related questions.
- Key molecules and functional subsets of regulatory T cells in maternal-fetal immune tolerance: Recent advances.
- Population pharmacokinetics and exposure-response analysis of durvalumab in patients with resectable stage II to IIIB (N2) NSCLC in the phase III AEGEAN study.
- CCDC137 stabilizes S100A6 to activate the PI3K/AKT pathway and drive acute myeloid leukemia progression.